Autopsy report · NCT03033511
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
Cause of deathOther
“Independent Data Monitoring Committee recommendation”
Life of this trial
- Ran for about 2 years 9 months before it stopped.
- 748 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- AbbVie
- Sponsor type
- Industry
- Conditions
- Small Cell Lung Cancer
- Interventions
- Placebo for dexamethasone; Placebo for rovalpituzumab tesirine; Rovalpituzumab tesirine; Dexamethasone
- Participants
- 748
- Sites
- 308
- Countries
- Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Estonia and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.